Dual-hormone Automated Insulin Delivery

Renard E, Ikegami H, Daher Vianna AG, et al. The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. Diabetes Metab Res Rev 2021;37(7):e3430. https://doi.org/10.1002/dmrr.3430

Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in di- abetes. N Engl J Med 2013;369(4):362-72. https://doi.org/10.1056/NE- JMra1215228

Peters TM, Haidar A. Dual-hormone artificial pancreas: benefits and limi- tations compared with single-hormone systems. Diabet Med 2018; 35(4):450-9. https://doi.org/10.1111/dme.13581

Blauw H, Wendl I, DeVries JH, Heise T, Jax T, PCDIAB consortium. Pharma- cokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels. Diabetes Obes Metab 2016;18(1):34-9. https://doi.org/10.1111/dom.12571

El Youssef J, Castle JR, Bakhtiani PA, et al. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care 2014;37(11):3054-60.https://doi.org/10.2337/dc14-0803

Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371(4):313-25. https://doi.org/10.1056/NEJMoa1314474

Haidar A, Legault L, Matteau-Pelletier L, et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pan- creas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2015;3(8):595-604. https://doi.org/10.1016/S2213- 8587(15)00141-2

Taleb N, Emami A, Suppere C, et al. Efficacy of single-hormone and dual- hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial. Diabetologia 2016;59(12):2561-71. https://doi.org/10.1007/s00125-016-4107-0

Zeng B, Jia H, Gao L, Yang Q, Yu K, Sun F. Dual-hormone artificial pancreas for glucose control in type 1 diabetes: A meta-analysis. Diabetes Obes Metab 2022;24(10):1967-75. https://doi.org/10.1111/dom.14781

Pieber TR, Aronson R, Hovelmann U, et al. Dasiglucagon-a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: Results of phase 3 randomized double-blind clinical trial. Diabetes Care 2021;44(6):1361-7. https://doi.org/10.2337/DC20-2995

Hawkes CP, De Leon DD, Rickels MR. Novel preparations of glucagon for the prevention and treatment of hypoglycemia. Curr Diab Rep 2019; 19(10):97. https://doi.org/10.1007/s11892-019-1216-4

Rickels MR, DuBose SN, Toschi E, et al. Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes. Diabetes Care 2018;41(9):1909-16. https://doi.org/10.2337/dc18-0051

Haymond MW, DuBose SN, Rickels MR, et al. Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes. J Clin Endocrinol Metab 2017;102(8):2994-3001. https://doi.org/10.1210/jc.2017-00591

Ilkowitz JT, Katikaneni R, Cantwell M, Ramchandani N, Heptulla RA. Adju- vant liraglutide and insulin versus insulin monotherapy in the closed-loop system in type 1 diabetes: a randomized open-labeled crossover design trial. J Diabetes Sci Technol 2016;10(5):1108-14. https://doi.org/10.1177/1932206816647976

Tsoukas MA, Majdpour D, Yale JF, et al. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial. Lancet Digit Health 2021;3(11):e723-e32. https://doi.org/10.1016/S2589-7500(21)00139-4

Brand-Eubanks D. Gvoke HypoPen: An auto-injector containing an inno- vative, liquid-stable glucagon formulation for use in severe acute hypoglycemia. Clin Diabetes 2019;37(4):393-4. https://doi.org/10.2337/cd19-0040